Recursion Pharmaceuticals

Recursion Pharmaceuticals News

News

0

Ticker

RXRX

ISIN

US75629V1044

Revenue Net Income P/E P/S EBIT Dividend Directors Dealings Stocks Market capitalization Debt Liabilities Equity AAQS Employees ROE ROA ROCE News Documents

Recursion Pharmaceuticals Eulerpool News

8/5/2026, 10:36:11 AM
Roche und Recursion: KI-Wirkstoffforschung schlägt Bürokratie
August 5
Roche and Recursion: AI Drug Discovery Wins Where Bureaucrats Fail
2/18/2026, 4:49:24 PM
US-Aktienmarkt zwischen KI-Sorgen und technischen Ausschlägen
February 18
US Stock Market Between AI Concerns and Technical Fluctuations
2/18/2026, 2:46:05 PM
Erholungsversuch an den US-Börsen: Tech-Giganten im Fokus
February 18
Attempted Recovery on US Stock Markets: Tech Giants in Focus
1/6/2025, 2:13:27 PM
Nvidia setzt auf KI-Innovationen: SoundHound AI und Nebius im Fokus
January 6
Nvidia focuses on AI innovations: SoundHound AI and Nebius in the spotlight
12/21/2024, 6:20:35 PM
KI-Unternehmen Recursion Pharmaceuticals bietet spannende Aussichten für 2025
December 21
AI company Recursion Pharmaceuticals offers exciting prospects for 2025
12/21/2024, 3:53:01 PM
Die Zukunft der Medizin: Recursion Pharmaceuticals als potenzieller Renditebringer
December 21
The Future of Medicine: Recursion Pharmaceuticals as a Potential Source of Returns
11/2/2024, 1:56:57 PM
Biotechnologie mit Millionärspotenzial: Ein Blick auf Recursion Pharmaceuticals
November 2
Biotechnology with Millionaire Potential: A Look at Recursion Pharmaceuticals
10/12/2024, 5:20:13 AM
Der Aufstieg von Edge-AI: Die Zukunft des Konsumentenmarktes?
October 12
The Rise of Edge AI: The Future of the Consumer Market?
10/11/2024, 12:18:07 PM
Recursion Pharmaceuticals übernimmt Exscientia: Eine Fusion zur Beschleunigung der Wirkstoffforschung
October 11
Recursion Pharmaceuticals acquires Exscientia: A merger to accelerate drug discovery
10/11/2024, 11:35:37 AM
Ark Invest setzt auf AMD – Semiconductors im Fokus
October 11
Ark Invest focuses on AMD – Semiconductors in the spotlight
9/9/2024, 2:40:07 AM
ARK-Investment: Einblicke in Cathie Woods Strategie und ihre kontroversen Entscheidungen
September 9
ARK-Investment: Insights into Cathie Wood's Strategy and Her Controversial Decisions
8/29/2024, 4:30:58 AM
Revolution im Gesundheitswesen: Künstliche Intelligenz entlastet knappe Ressourcen
August 29
Revolution in Healthcare: Artificial Intelligence Eases Strain on Scarce Resources
8/9/2024, 3:13:00 AM
Pharmatech-Giganten verschmelzen: Exscientia und Recursion bündeln Kräfte
August 9
Pharmatech Giants Merge: Exscientia and Recursion Join Forces
8/8/2024, 4:33:24 PM
Recursion Pharmaceuticals kauft Exscientia: Ein Zeichen für die Zukunft der KI im Gesundheitswesen
August 8
Recursion Pharmaceuticals buys Exscientia: A Sign for the Future of AI in Healthcare

Recursion Pharmaceuticals Stock News

Recursion Pharmaceuticals is being monitored by journalists and investors worldwide. We gather the latest Recursion Pharmaceuticals news here.

Recursion Pharmaceuticals Stock Press Releases

Recursion Pharmaceuticals regularly publishes news on the company's website that are relevant for investors.

Recursion Pharmaceuticals News 2026

This page contains all current news, analysis and press releases for Recursion Pharmaceuticals stock (RXRX, ISIN: US75629V1044). This includes Eulerpool news, company analysis and official press releases. Data is updated regularly to provide investors with a complete overview of the latest developments at Recursion Pharmaceuticals.

Recursion Pharmaceuticals Stock

Recursion Pharmaceuticals Recursion Pharmaceuticals Inc is a biotechnology company based in Salt Lake City, Utah, operating in the Health Care sector. The company went public via an IPO on April 16, 2021. It employs approximately 600 people. Recursion Pharmaceuticals utilizes automation, artificial intelligence, and machine learning technologies to discover novel medicines. The company's platform, referred to as the Recursion Operating System (OS), integrates physical and digital components to map and navigate biological and chemical relationships. The company's approach involves iterative loops between wet lab biology and chemistry data, organized into cycles with computational tools to translate digital hypotheses into validated insights. Recursion Pharmaceuticals has clinical programs including REC-994, REC-2282, REC-4881, and REC-3964. REC-994 is described as an orally bioavailable, superoxide scavenger small molecule being developed for the treatment of cerebral cavernous malformations. The company's website is www.recursion.com. It is listed under the ticker symbol RXRX with ISIN US75629V1044. The company's headquarters are located in Salt Lake City, Utah.